Back
Resmed Inc (RMD)
Health CareRMD · NEW YORK STOCK EXCHANGE, INC. · USD
New to investing? How to read this page →$232.45
+0.40%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$10.43
ROE
25.2%
Gross margin
62.2%
Debt/Equity
0.13x
Revenue growth
10.8%
Resmed Inc — company intelligence
Earnings surprises
Q4 2026$2.95 vs $2.92 est+1.1%
Q3 2026$2.86 vs $2.82 est+1.3%
Q2 2026$2.81 vs $2.75 est+2.1%
Q1 2026$2.55 vs $2.58 est-1.2%
Analyst consensus · 25 analysts
12 Buy11 Hold2 Sell
Updated Aug 24, 2026
Insider activity · 90 days
0 buys2 sellsnet -8,269 shares
FARRELL PETER CSell 8,000 · Aug 5, 2026
Farrell Michael J.other 4,991 · Jul 7, 2026
Farrell Michael J.other 4,991 · Jun 8, 2026
Recent SEC filings
10-K — Annual reportAug 13, 2026
4 — Insider transaction reportAug 11, 2026
8-K — Material event reportAug 6, 2026
Latest news
Rothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230 — Benzinga · 6d ago
ResMed (RMD) Stock May Be 31% Undervalued After Soft FY27 Outlook — Yahoo · 1w ago
Is Recall-Hit Outlook and Bigger Payout Altering The Investment Case For ResMed (RMD)? — Yahoo · 2w ago
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists — Yahoo · 2w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.